Date: 2017-04-17
Type of information: Collaboration agreement
Compound: AAV vectors
Company: Crispr Therapeutics (Switzerland - UK) Casebia Therapeutics (UK) StrideBio (USA - NC)
Therapeutic area: Technology - Services
Type agreement: collaboration, licensing
Action mechanism: gene therapy. StrideBio’s AAV vector development platform makes use of structure-guided evolution to discover novel capsids with improved properties for in vivo gene delivery applications. The underlying technology is based on the work of Dr. Aravind Asokan at the University of North Carolina at Chapel Hill and Dr. Mavis Agbandje-McKenna at the University of Florida.
Disease:
Details:
- • On April 17, 2017, Crispr Therapeutics and Casebia Therapeutics, a joint-venture established by CRISPR Therapeutics and Bayer AG for developing CRISPR-based therapeutics in select disease areas, announced they have signed a collaboration agreement with StrideBio, a US-based company developing novel AAV vectors for in vivo gene delivery applications.
- Under the terms of the agreement, StrideBio will use its proprietary platform to develop AAV vectors with improved properties such as tissue specificity and reduced susceptibility to immune responses. CRISPR Therapeutics and Casebia will have an option to exclusively license AAV vectors with desired properties for use in their in vivo gene-editing programs. StrideBio will receive development funding, milestones and royalties on licensed vectors, and retain certain rights to use the novel AAV vectors for gene therapy applications.
Financial terms:
Latest news:
Is general: Yes
